Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2018 06:35 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports First Quarter 2018 Financial Results and Management Transition

- Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 - - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN,...
February 26, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy

NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
February 22, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results

Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief...
February 09, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
December 20, 2017 12:12 ET | Source: Achillion Pharmaceuticals, Inc.

CORRECTION - Achillion Pharmaceuticals, Inc.

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
December 20, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
November 01, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs

NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
October 24, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
May 02, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference

NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
March 21, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent...

Next Page keyboard_arrow_right